CCL2 and metastatic melanoma: Clinically, intratumoral CCL2 immunostaining negatively correlates with the number of CD8+ T cells in patients with hepatocellular carcinoma73 and pancreatic cancer patients with tumors expressing high CD8 and low CCL2 display significantly better survival.76 Absence of immunosuppressive monocytic cells appears to be important for response to checkpoint immunotherapies, as the frequency of CD11b+CD14+HLA‐DRlo cells was higher in metastatic melanoma patients who did not respond to anti‐PD‐1 immunotherapy compared to those that did respond and correlated with overall survival.77